Meeting
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
Authors
Jason Westin
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Jason Westin , Caron Alyce Jacobson , Julio C. Chavez , Anna Sureda , Franck Morschhauser , Bertram Glaß , Michael Dickinson , Andrew Davies , Ian W. Flinn , David G. Maloney , Martine Chamuleau , Michael Timothy Tees , Allen Xue , Shilpa Shahani , Olga Nikolajeva , Janet Kang , Aida Kaplan , Marco Andreas Schupp , Harry Miao , Elizabeth Shima Rich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05371093
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7578)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7578
Abstract #
TPS7578
Poster Bd #
129a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2023 ASCO Annual Meeting
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho